Sechenov School
Home › Biochemistry › Thymidylate Synthesis

Thymidylate Synthesis

For medical students2 min readUpdated 2026-10-10

Thymidylate synthesis is a vital biochemical process yielding deoxythymidine monophosphate (dTMP), a specific and essential component of DNA. The key step of this pathway is the methylation of deoxyuridine monophosphate (dUMP) requiring folate derivatives.

Main productdTMP (deoxythymidine monophosphate)
Key enzymeThymidylate synthase
Carbon donorN5,N10-methylene-THF
Rate regulationDependent on dihydrofolate reductase activity

Core Reaction: Conversion of dUMP to dTMP

The central event in thymidylate biosynthesis is the conversion of dUMP (deoxyuridine monophosphate) into dTMP. This reaction is absolutely required for subsequent DNA synthesis.

The process is catalyzed by the enzyme thymidylate synthase. For the reaction to proceed, the enzyme requires a coenzyme that acts as a single-carbon group donor: $N^5,N^{10}$-methylene-$H_4$-folate (a tetrahydrofolate derivative).

The reaction mechanism involves two consecutive steps:

  1. The single-carbon radical is transferred from the coenzyme and incorporated specifically into position 5 of the pyrimidine ring of the substrate (dUMP).
  2. The transferred methylene group is reduced to a methyl group. Critically, the hydrogen atoms required for this reduction are directly abstracted from the $H_4$-folate itself. Due to the loss of these hydrogen atoms, $H_4$-folate is oxidized into dihydrofolate ($H_2$-folate).

Regeneration of Active Folates

Because the active coenzyme is consumed and converted into its oxidized form ($H_2$-folate) during dTMP synthesis, active folate reserves must be continuously replenished to sustain nucleotide production. This process is driven by two key enzymes:

Sources of the Substrate (dUMP)

For dTMP synthesis to occur, the cell must ensure an adequate supply of the initial substrate, deoxyuridine monophosphate (dUMP). There are two main pathways for its production:

  1. Dephosphorylation of dUDP. Deoxyuridine diphosphate loses a phosphate group to become dUMP.
  2. The primary human pathway. This involves a longer chain of conversions starting with the dephosphorylation of deoxycytidine diphosphate (dCDP). The dCDP molecule is first dephosphorylated to deoxycytidine monophosphate (dCMP). Next, a hydrolytic deamination of dCMP is catalyzed by the enzyme dCMP deaminase. By removing the amino group, dCMP is converted directly into dUMP.

Regulation and Salvage Pathway

Thymidylate synthesis is tightly controlled by the cell. The levels and activity of the key enzymes in this pathway—thymidylate synthase and ribonucleotide reductase (RNR)—are regulated at the genetic level via induction of their synthesis. There is a direct correlation with the rate of DNA synthesis: the amounts of these enzymes spike sharply only when cells are actively preparing to divide and synthesize DNA.

In addition to the de novo pathway, actively dividing cells utilize a salvage pathway to reuse preformed components. The cell can scavenge preformed thymidine and convert it directly into dTMP. This reaction is catalyzed by thymidylate kinase (often referred to as thymidine kinase in salvage contexts), utilizing ATP as the phosphate donor.

Mnemonic

To remember folate regeneration enzymes: Dihydrofolate Reductase Delivers active Tetrahydrofolate, while Serine hydroxymethyltransferase Supplies the methylene group.

Frequently asked questions

Which drugs inhibit thymidylate synthase?

Thymidylate synthase is inhibited by the antineoplastic drug 5-fluorouracil.

  • 5-Fluorouracil (5-FU) undergoes metabolic activation to 5-fluoro-deoxyuridine monophosphate (5-FdUMP).

This metabolite acts as a suicide inhibitor. It binds to the enzyme's active site along with the coenzyme. Because the fluorine atom is tightly bound to carbon, a stable, unresolvable covalent ternary complex is formed ("Enzyme – Inhibitor – Coenzyme"). As a result, the enzyme is irreversibly blocked, dTMP synthesis halts, and cell division is arrested.

Which drugs inhibit dihydrofolate reductase?

Dihydrofolate reductase is inhibited by structural analogs of folic acid.

Such chemotherapeutic agents include:

  • Methotrexate
  • Aminopterin

These agents act as competitive inhibitors of the enzyme. They disrupt the reduction of dihydrofolate to tetrahydrofolate, depleting active coenzyme pools, reducing the rate of dUMP to dTMP conversion, and ultimately limiting DNA synthesis.

Which enzyme limits the rate of dTMP production?

Dihydrofolate reductase determines the rate of dTMP synthesis. It reduces dihydrofolate back to tetrahydrofolate, without which thymidylate synthase cannot continue functioning.

How is most dUMP produced in the human body?

The primary pathway is the dephosphorylation of dCDP to dCMP followed by hydrolytic deamination. The final step is mediated by dCMP deaminase.

What is the salvage pathway for thymidylate synthesis?

It is the recycling pathway for the preformed nucleoside thymidine. Using thymidine kinase and ATP energy, thymidine is phosphorylated directly into dTMP.

Go deeper

More topics in Biochemistry

Ribonucleotide Reductase: Structure, Mechanism and RegulationOxidoreductasesImmunoglobulin GenesGluconeogenesisProtein Digestion in the StomachCalcium and Phosphorus MetabolismImmunodeficiencies Associated with Nucleotide MetabolismDisulfide Bonds in ProteinsTransferasesDNA MutationsRegulation of Gluconeogenesis and GlycolysisFluid and Electrolyte BalanceBiochemistry →